Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Ron_Cohen
|
| gptkbp:focusesOn |
gptkb:Parkinson's_disease
multiple sclerosis neurological disorders |
| gptkbp:founded |
1995
|
| gptkbp:founder |
gptkb:Ron_Cohen
|
| gptkbp:headquarters_location |
gptkb:Ardsley,_New_York,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Acorda Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:numberOfEmployees |
approximately 150 (as of 2023)
|
| gptkbp:parentOrganization |
Merz Therapeutics (as of 2024)
|
| gptkbp:product |
gptkb:Ampyra
Inbrija |
| gptkbp:tradedOn |
NASDAQ: ACOR
|
| gptkbp:website |
https://www.acorda.com/
|
| gptkbp:bfsParent |
gptkb:fampridine
|
| gptkbp:bfsLayer |
7
|